Creative Medical Technology (CELZ) Competitors

$2.21 -0.07 (-3.07%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$2.24 +0.02 (+1.13%)

As of 08:03 AM Eastern

CELZ vs. HOWL, NNVC, NRSN, TPST, and SKYE

Should you buy Creative Medical Technology stock or one of its competitors? MarketBeat compares Creative Medical Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creative Medical Technology include Werewolf Therapeutics (HOWL), NanoViricides (NNVC), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does Creative Medical Technology compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Creative Medical Technology's return on equity of -88.38% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Creative Medical Technology	N/A	-88.38%	-84.71%

In the previous week, Werewolf Therapeutics had 14 more articles in the media than Creative Medical Technology. MarketBeat recorded 16 mentions for Werewolf Therapeutics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 2.46 beat Werewolf Therapeutics' score of -0.30 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Creative Medical Technology	Very Positive

Werewolf Therapeutics currently has a consensus target price of $3.75, indicating a potential upside of 542.23%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Creative Medical Technology has lower revenue, but higher earnings than Werewolf Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	15.09	-$60.82M	-$1.24	N/A
Creative Medical Technology	$6K	1,361.73	-$5.99M	-$2.14	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market.

Summary

Werewolf Therapeutics beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to NanoViricides?

Creative Medical Technology (NASDAQ:CELZ) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NanoViricides' return on equity of -87.90% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
NanoViricides	N/A	-87.90%	-78.69%

In the previous week, Creative Medical Technology and Creative Medical Technology both had 2 articles in the media. Creative Medical Technology's average media sentiment score of 2.46 beat NanoViricides' score of 0.65 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
NanoViricides	Positive

Creative Medical Technology has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$6K	1,361.73	-$5.99M	-$2.14	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.48	N/A

Summary

NanoViricides beats Creative Medical Technology on 7 of the 12 factors compared between the two stocks.

How does Creative Medical Technology compare to NeuroSense Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

NeuroSense Therapeutics has a consensus target price of $8.50, indicating a potential upside of 921.02%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Creative Medical Technology had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for NeuroSense Therapeutics. Creative Medical Technology's average media sentiment score of 2.46 beat NeuroSense Therapeutics' score of 1.87 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
NeuroSense Therapeutics	Very Positive

NeuroSense Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
NeuroSense Therapeutics	N/A	N/A	N/A

Creative Medical Technology has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$6K	1,361.73	-$5.99M	-$2.14	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 1.7% of Creative Medical Technology shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Creative Medical Technology has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Summary

NeuroSense Therapeutics beats Creative Medical Technology on 8 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to Tempest Therapeutics?

Creative Medical Technology (NASDAQ:CELZ) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Creative Medical Technology has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.75, suggesting that its share price is 275% less volatile than the broader market.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Creative Medical Technology. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 2.46 beat Tempest Therapeutics' score of 0.96 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
Tempest Therapeutics	Positive

Creative Medical Technology has higher revenue and earnings than Tempest Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$6K	1,361.73	-$5.99M	-$2.14	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.64	N/A

Creative Medical Technology's return on equity of -88.38% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Tempest Therapeutics	N/A	-309.60%	-115.81%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tempest Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Creative Medical Technology beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Creative Medical Technology compare to Skye Bioscience?

Creative Medical Technology (NASDAQ:CELZ) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by insiders. Comparatively, 4.5% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skye Bioscience had 5 more articles in the media than Creative Medical Technology. MarketBeat recorded 7 mentions for Skye Bioscience and 2 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 2.46 beat Skye Bioscience's score of 0.05 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
Skye Bioscience	Neutral

Creative Medical Technology has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

Creative Medical Technology's return on equity of -88.38% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-88.38%	-84.71%
Skye Bioscience	N/A	-217.27%	-162.39%

Skye Bioscience has a consensus price target of $9.80, suggesting a potential upside of 1,095.56%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Creative Medical Technology has higher revenue and earnings than Skye Bioscience. Creative Medical Technology is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$6K	1,361.73	-$5.99M	-$2.14	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

Summary

Skye Bioscience beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.17M	$3.42B	$6.31B	$12.28B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-1.03	18.67	21.03	25.58
Price / Sales	1,361.73	301.04	552.34	78.22
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.33	6.75	9.83	6.66
Net Income	-$5.99M	$24.11M	$3.55B	$333.63M
7 Day Performance	-3.49%	-0.53%	-0.52%	-0.12%
1 Month Performance	-3.49%	0.34%	1.20%	3.93%
1 Year Performance	8.33%	78.62%	41.25%	36.07%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.3082 of 5 stars	$2.21 -3.1%	N/A	+10.5%	$8.17M	$6K	N/A	5	Earnings Report
HOWL Werewolf Therapeutics	2.5428 of 5 stars	$0.65 -2.9%	$3.75 +476.7%	-42.8%	$32.54M	$1.88M	N/A	40	Earnings Report Insider Trade Gap Down
NNVC NanoViricides	0.5506 of 5 stars	$1.46 flat	N/A	+37.6%	$31.53M	N/A	N/A	20
NRSN NeuroSense Therapeutics	3.6349 of 5 stars	$0.90 -5.5%	$8.50 +846.7%	-33.9%	$30.92M	N/A	N/A	10	Gap Up High Trading Volume
TPST Tempest Therapeutics	2.4457 of 5 stars	$2.02 -6.0%	N/A	-72.9%	$30.84M	N/A	N/A	20	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. HOWL, NNVC, NRSN, TPST, and SKYE

How does Creative Medical Technology compare to Werewolf Therapeutics?

Summary

How does Creative Medical Technology compare to NanoViricides?

Summary

How does Creative Medical Technology compare to NeuroSense Therapeutics?

Summary

How does Creative Medical Technology compare to Tempest Therapeutics?

Summary

How does Creative Medical Technology compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. HOWL, NNVC, NRSN, TPST, and SKYE

How does Creative Medical Technology compare to Werewolf Therapeutics?

Is HOWL or CELZ more profitable?

Does the media refer more to HOWL or CELZ?

Do analysts prefer HOWL or CELZ?

Which has higher earnings & valuation, HOWL or CELZ?

Do insiders and institutionals believe in HOWL or CELZ?

Which has more volatility and risk, HOWL or CELZ?

Summary

How does Creative Medical Technology compare to NanoViricides?

Do analysts prefer CELZ or NNVC?

Do institutionals and insiders believe in CELZ or NNVC?

Is CELZ or NNVC more profitable?

Does the media prefer CELZ or NNVC?

Which has more risk and volatility, CELZ or NNVC?

Which has stronger earnings and valuation, CELZ or NNVC?

Summary

How does Creative Medical Technology compare to NeuroSense Therapeutics?

Do analysts recommend CELZ or NRSN?

Does the media favor CELZ or NRSN?

Is CELZ or NRSN more profitable?

Which has preferable valuation and earnings, CELZ or NRSN?

Do insiders & institutionals believe in CELZ or NRSN?

Which has more volatility and risk, CELZ or NRSN?

Summary

How does Creative Medical Technology compare to Tempest Therapeutics?

Which has more risk and volatility, CELZ or TPST?

Does the media prefer CELZ or TPST?

Which has stronger earnings and valuation, CELZ or TPST?

Is CELZ or TPST more profitable?

Do analysts rate CELZ or TPST?

Do insiders and institutionals have more ownership in CELZ or TPST?

Summary

How does Creative Medical Technology compare to Skye Bioscience?

Do insiders & institutionals have more ownership in CELZ or SKYE?

Does the media favor CELZ or SKYE?

Which has more risk & volatility, CELZ or SKYE?

Is CELZ or SKYE more profitable?

Do analysts recommend CELZ or SKYE?

Which has better valuation and earnings, CELZ or SKYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools